Clinical Trials Logo

Filter by:
NCT ID: NCT05691205 Recruiting - Clinical trials for Lung Transplant; Complications

Identifying Optimal PEEP After Lung Transplantation

PEEP-LuTX
Start date: January 31, 2023
Phase: N/A
Study type: Interventional

Lung Transplantation (LuTX) is the curative treatment for selected patients with end-stage lung disease. Primary Graft Dysfunction (PGD), a specific form of respiratory failure occurring within the first 72 hours after graft reperfusion, represents the most common complication after LuTX. Actual recommendation regarding management of mechanical ventilation of the lung graft immediately after LuTX are based only on opinion experts and not on clinical trials. Optimization of Positive End-Expiratory Pressure might contribute to both prevention and treatment of PGD. In this interventional single-center non-pharmacological study (with medical device), in the immediate postoperative period of patients who are undergone LuTX, we will evaluate the effects of varying levels of PEEP upon: - lung and chest wall mechanics, - intrapulmonary shunt fraction; - distribution of ventilation and perfusion; - gas exchange. The final aim is to find the optimal level of PEEP in this patient's cohort

NCT ID: NCT05690854 Recruiting - Clinical trials for Transposition of Great Arteries

Cardiovascular Magnetic Resonance in Adults With SysTemic Right Ventricle (STAR)

STAR
Start date: November 29, 2022
Phase:
Study type: Observational

The main aim of the study is to explore HFs in SRV, comparing their magnitude and direction with that of subpulmonary RV and systemic LV. As a secondary aim, possible association or correlation will be investigated between SRV energetics and: i) patient functional parameters, e.g., the results from cardiopulmonary exercise test (CPET), ii) patient clinical status, including the occurrence of adverse outcome (a composite of death, hospitalization for heart failure, cardiovascular arrest, sustained arrhythmias).

NCT ID: NCT05690412 Recruiting - Ampullary Cancer Clinical Trials

Efficacy and Safety of Endoscopic Papillectomy in the Treatment of Ampullary Neoplasms.

PaNETh
Start date: April 1, 2022
Phase:
Study type: Observational

The aim of our study is to provide data on the efficacy and safety of endoscopic papillectomy, by including consecutive patients treated after 2015, when first guidelines on endoscopic management of ampullary neoplasms were available.

NCT ID: NCT05689710 Recruiting - Metabolic Syndrome Clinical Trials

The Effects of Inositol on Glucose Metabolism in Patients With Metabolic Syndrome at Risk of Cardiac Fibrosis

Start date: December 23, 2022
Phase: N/A
Study type: Interventional

The study aims to evaluate the effects of an oral supplementation based on inositols and alpha-lactalbumin on principals metabolic parameters in patients with metabolic syndrome at risk of cardiac fibrosis

NCT ID: NCT05689619 Recruiting - Breast Cancer Clinical Trials

SILibinin in NSCLC and BC Patients With Single Brain METastasis (SILMET)

SILMET
Start date: September 1, 2023
Phase: N/A
Study type: Interventional

This study aims to evaluate the efficacy of silibinin in preventing recurrence in the brain after complete resection of a brain metastasis (BM) from non-small-cell lung cancer (NSCLC) or breast cancer (BC).

NCT ID: NCT05689476 Recruiting - Clinical trials for Lung Transplantation

Electrical Activity of the Diaphragm and Respiratory Mechanics During NAVA

NAVAMECH
Start date: December 27, 2022
Phase: N/A
Study type: Interventional

Protective ventilatory strategy should be applied to reduce both ventilator-induced lung injury (VILI) and ventilator-induced diaphragm dysfunction (VIDD) after Lung Transplantation (LTx). Neurally Adjusted Ventilatory Assist (NAVA) is an assisted ventilation mode in which respiratory support is coordinated by the electrical activity of the diaphragm (EAdi). Aim of the study is to assess the physiological relationship between neural respiratory drive as assessed by EAdi and tidal volume, driving pressure and mechanical power, at different levels of ventilatory assist, in the absence of pulmonary vagal afferent feedback.

NCT ID: NCT05687266 Recruiting - NSCLC Clinical Trials

Phase III, Open-label, First-line Study of Dato-DXd in Combination With Durvalumab and Carboplatin for Advanced NSCLC Without Actionable Genomic Alterations

AVANZAR
Start date: December 29, 2022
Phase: Phase 3
Study type: Interventional

This is a Phase III, randomized, open-label, multicenter, global study to compare the efficacy and safety of Datopotamab Deruxtecan (Dato-DXd) in combination with durvalumab and carboplatin compared with pembrolizumab in combination with histology-specific platinum-based chemotherapy as first-line treatment of adults with stage IIIB, IIIC, or IV NSCLC without actionable genomic alterations (including sensitizing EGFR mutations, and ALK and ROS1 rearrangements).

NCT ID: NCT05687084 Recruiting - Clinical trials for Endometrial Neoplasms

Uterine Manipulator Versus no Uterine Manipulator in Endometrial Cancer Trial

MANEC
Start date: January 16, 2023
Phase: N/A
Study type: Interventional

Minimally invasive surgery is the recommended approach in endometrial cancer (EC) patients based on the results of two randomized controlled trials, given its advantages without compromised oncologic outcomes. The uterine manipulator is commonly used in benign and malignant pathologies to perform a laparoscopic or robotic hysterectomy. However, although regularly used, the uterine manipulator adoption in EC is a controversial technical aspect due to the raised concerns regarding the possible risk of disruption of the tumor mass, the spread of malignant cells, and seeding of the disease, particularly at the level of the vaginal cuff or spread of tumor cells, with increased risk of recurrence and death due to EC. On that basis, given that hysterectomy without a uterine manipulator is feasible, only a randomized controlled trial comparing oncologic outcomes in EC patients after use versus not use of the uterine manipulator will be able to provide high-quality evidence to answer this critical question and allow or exclude the use of a uterine manipulator during minimally invasive hysterectomy for EC.

NCT ID: NCT05686707 Recruiting - Clinical trials for Angina CCS Classe II-IV - IMR, RFR, FFR,CFR

Characterization of Different Phenotypes of Microvascular Dysfunction and Their Impact on Angina Severity in Patients With Chronic Angina in the Absence of Obstructive Coronary Artery Disease.

MiVa
Start date: July 18, 2022
Phase:
Study type: Observational [Patient Registry]

The aim of the present study will be to identify different phenotypes of microvascular dysfunction and their associations with the severity of anginal symptoms assessed through the Seattle Angina Questionnaire(SAQ-7).

NCT ID: NCT05686551 Recruiting - Huntington Disease Clinical Trials

GENERATION HD2. A Study to Evaluate the Safety, Biomarkers, and Efficacy of Tominersen Compared With Placebo in Participants With Prodromal and Early Manifest Huntington's Disease.

Start date: February 3, 2023
Phase: Phase 2
Study type: Interventional

This study will evaluate the safety, biomarkers, and efficacy of tominersen compared with placebo in participants with prodromal and early manifest Huntington's Disease.